Journal article
Efficacy and safety of oral methazolamide in patients with type 2 diabetes: A 24-week, placebo-controlled, double-blind study
RW Simpson, GC Nicholson, J Proietto, A Sarah, KM Sanders, G Phillips, J Chambers, R MacGinley, N Orford, K Walder, G Krippner, K Skoff, VJ Wacher
Diabetes Care | Published : 2014
DOI: 10.2337/dc14-1038
Abstract
OBJECTIVE: To evaluate the safety and efficacy of methazolamide as a potential therapy for type 2 diabetes. RESEARCH DESIGN AND METHODS: This double-blind, placebo-controlled study randomized 76 patients to oral methazolamide (40 mg b.i.d.) or placebo for 24 weeks. The primary efficacy end point for methazolamide treatment was a placebo-corrected reduction in HbA1c from baseline after 24 weeks (ΔHbA1c). RESULTS: Mean ± SD baseline HbA1c was 7.1 ± 0.7% (54 ± 5 mmol/mol; n 5 37) and 7.4 ± 0.6% (57 ± 5 mmol/mol; n 5 39) in the methazolamide and placebo groups, respectively. Methazolamide treatment was associated with a ΔHbA1c of -0.39% (95% CI -0.82, 0.04; P < 0.05) (-4.3 mmol/mol [- 9.0, 0.4])..
View full abstractGrants
Funding Acknowledgements
This study was funded by Verva Pharmaceuticals, Ltd. R. W. S. received funding from Verva Pharmaceuticals, Ltd., to conduct the study and was compensated for attending advisory meetings. K. S. and V.J.W. were employed by Verva Pharmaceuticals during the course of the study, and G. K. received funding from Verva Pharmaceuticals as a consultant during the course of the study. K.W.'s laboratory at Deakin University has previously been funded by Verva Pharmaceuticals to undertake preclinical studies. No other potential conflicts of interest relevant to this article were reported.